Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Single Center Study on Comparison of the Clinical Efficacy and Patients Satisfaction of Cyporin N 0.05% Eye Drops in Dry Eye Patients with meibomian gland dysfunction

Next Previous
Search
Trial Profile

Prospective, Single Center Study on Comparison of the Clinical Efficacy and Patients Satisfaction of Cyporin N 0.05% Eye Drops in Dry Eye Patients with meibomian gland dysfunction

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Dry eyes; Meibomian gland dysfunction
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 May 2022 Primary endpoint (Ocular Surface Disease Index (OSDI) score) has been met, according to published in the Japanese Journal of Ophthalmology.
    • 01 May 2022 Results assessing efficacy of topical cyclosporin A in obstructive meibomian gland dysfunction, published in the Japanese Journal of Ophthalmology.
    • 23 Sep 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top